Insider Trading Alert - VNTV, SNCR And AMRI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, July 2, 2014, 88 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $147.42 to $14,640,500.00.

Highlighted Stocks Traded by Insiders:

Vantiv (VNTV) - FREE Research Report

Cole Royal, who is President, Fin. Institutions at Vantiv, sold 19,351 shares at $33.81 on July 2, 2014. Following this transaction, the President, Fin. Institutions owned 114,534 shares meaning that the stake was reduced by 14.45% with the 19,351-share transaction.

The shares most recently traded at $33.52, down $0.29, or 0.87% since the insider transaction. Historical insider transactions for Vantiv go as follows:

  • 4-Week # shares sold: 20,149
  • 12-Week # shares sold: 157,649
  • 24-Week # shares sold: 19.0 million

The average volume for Vantiv has been 1.5 million shares per day over the past 30 days. Vantiv has a market cap of $4.7 billion and is part of the services sector and diversified services industry. Shares are up 3.4% year-to-date as of the close of trading on Wednesday.

Vantiv, Inc. provides electronic integrated payment processing services in the United States. It operates in two segments, Merchant Services and Financial Institution Services. The company has a P/E ratio of 38.9. Currently, there are 7 analysts who rate Vantiv a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VNTV - FREE

TheStreet Quant Ratings rates Vantiv as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, notable return on equity, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Vantiv Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Synchronoss Technologies (SNCR) - FREE Research Report

Hilbert Paula J, who is Executive Vice President at Synchronoss Technologies, sold 157 shares at $33.73 on July 2, 2014. Following this transaction, the Executive Vice President owned 27,722 shares meaning that the stake was reduced by 0.56% with the 157-share transaction.

The shares most recently traded at $35.35, up $1.62, or 4.58% since the insider transaction. Historical insider transactions for Synchronoss Technologies go as follows:

  • 4-Week # shares sold: 158
  • 12-Week # shares sold: 1,225
  • 24-Week # shares sold: 96,469

The average volume for Synchronoss Technologies has been 394,000 shares per day over the past 30 days. Synchronoss Technologies has a market cap of $1.5 billion and is part of the technology sector and computer software & services industry. Shares are up 13.78% year-to-date as of the close of trading on Wednesday.

Synchronoss Technologies, Inc. provides cloud solutions and software-based activation for connected devices worldwide. The company has a P/E ratio of 46.6. Currently, there are 7 analysts who rate Synchronoss Technologies a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SNCR - FREE

TheStreet Quant Ratings rates Synchronoss Technologies as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Synchronoss Technologies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Albany Molecular Research (AMRI) - FREE Research Report

Henderson Lori M, who is SVP, Secretary & Gen. Counsel at Albany Molecular Research, sold 2,500 shares at $20.62 on July 2, 2014. Following this transaction, the SVP, Secretary & Gen. Counsel owned 47,063 shares meaning that the stake was reduced by 5.04% with the 2,500-share transaction.

The shares most recently traded at $21.89, up $1.27, or 5.8% since the insider transaction. Historical insider transactions for Albany Molecular Research go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 2,500
  • 12-Week # shares bought: 40,000
  • 12-Week # shares sold: 8,397
  • 24-Week # shares bought: 40,000
  • 24-Week # shares sold: 13,897

The average volume for Albany Molecular Research has been 432,300 shares per day over the past 30 days. Albany Molecular Research has a market cap of $688.7 million and is part of the health care sector and drugs industry. Shares are up 114.09% year-to-date as of the close of trading on Wednesday.

Albany Molecular Research, Inc., a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. The company has a P/E ratio of 70.9. Currently, there is 1 analyst who rates Albany Molecular Research a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMRI - FREE

TheStreet Quant Ratings rates Albany Molecular Research as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, solid stock price performance, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Albany Molecular Research Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

PayPal Is Headed to a $100 Billion Valuation

PayPal Is Headed to a $100 Billion Valuation

Despite Bitcoin Surge, Square Stock Is Tumbling

Despite Bitcoin Surge, Square Stock Is Tumbling

PayPal's Plan to Make Money From Venmo Comes Into Focus Ahead of Earnings

PayPal's Plan to Make Money From Venmo Comes Into Focus Ahead of Earnings

Vantiv-Worldpay Deal an Inversion That Wasn't

Vantiv-Worldpay Deal an Inversion That Wasn't

The Amazon Effect Extends to Payments Industry With Vantiv-Worldpay Deal

The Amazon Effect Extends to Payments Industry With Vantiv-Worldpay Deal